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Fungal burden in the cerebrospinal fluid is an important determinant of mortality in cryptococcal meningitis, but its use in aid-
ing clinical decision making is hampered by the time involved to perform quantitative cultures. Here, we demonstrate the poten-
tial of flow cytometry as a novel and rapid technique to address this issue.
Cryptococcal meningitis (CM) remains one of the common-est causes of meningitis in sub-Saharan Africa and a signif-
icant cause of death among persons with HIV-1 infection (1,
2). Cerebrospinal fluid (CSF) fungal burden is an important
determinant of mortality but requires quantitative culture, a
time-consuming process taking several days, limiting its use-
fulness as a clinical aide in decision making (3). Recent in vitro
work using broth dilutions of Cryptococcus neoformans demon-
strated a very close association between the number of crypto-
cocci counted using a flow cytometer and quantitative culture
(4). This raises the possibility that flow cytometry is a useful
technique to rapidly assess fungal burden in patients with
cryptococcal meningitis. However, no studies have examined
this technique on ex vivo samples. We addressed this by per-
forming flow cytometry counting of cryptococci in CSF sam-
ples from patients with HIV-1-associated CM and compared
these counts with measurement of fungal burden using quan-
titative CSF culture. This study formed part of a larger body of
work aimed primarily at examining the CSF immune response
in CM.
A prospective cohort study was conducted in Cape Town,
South Africa. All participants provided written informed con-
sent; surrogate consent was obtained from the next of kin for
patients with impaired consciousness. Ethical approval was ob-
tained from the University of Cape Town (Cape Town, South
Africa) and Liverpool School of Tropical Medicine (Liverpool,
United Kingdom) research ethics committees. HIV-infected
persons age18 years with a first episode of cryptococcal men-
ingitis (diagnosed by antigen test or culture) were enrolled
within 48 h of diagnosis, and lumbar puncture performed to
measure the cerebrospinal fluid (CSF) opening pressure. CSF
fungal burden was assessed with quantitative culture (5) and
cryptococcal antigen (CrAg) titer (CrAg lateral flow assay
[LFA]; Immy, USA), as previously described (6). The volume
of remaining CSF was measured and the cells pelleted using
centrifugation; this was incubated on ice with an amine viability dye
(Aqua; Invitrogen) and anti-CD45-PECy5.5 (BioLegend) and then
at room temperature with flow-activated cell sorting (FACS) lys-
ing solution (BD Biosciences), protected from light at all times.
Cells were fixed using 2% paraformaldehyde and analyzed within
24 h on a BD LSRFortessa flow cytometer using the FACSDiva
software (BD Biosciences). A forward scatter threshold of 5,000
was used to avoid including any debris in counting; the sample
was acquired in its entirety to allow a calculation of cell counts.
Compensation was performed using species-appropriate com-
pensation beads (BDBiosciences; Invitrogen). Datawere analyzed
using Flow Jo version 9.5.3 (Tree Star software) (Fig. 1). Crypto-
cocci were defined as CSF cells negative for the panleukocyte
marker CD45. The counts for the whole sample were divided by
the CSF volume to obtain Cryptococcus counts per milliliter of
CSF. Statistical analyses were performed using Stata version 12
(StataCorp).
Sixty HIV-infected patients with cryptococcal meningitis were
enrolled, with a median CD4 count of 34 cells/l of CSF. CSF
samples were available for 58 participants, 36 of whom had not
received any amphotericinBprior to enrollment. ThemedianCSF
volume collected for flow cytometry was 7 ml (interquartile range
[IQR], 4.5 to 8 ml). The median fungal burden was 4.74 log10
CFU/ml of CSF (IQR, 3.5 to 5.75 log10 CFU/ml), as measured by
quantitative culture, and 4.53 log10 Cryptococcus yeasts per ml of
CSF (IQR, 3.33 to 5.21 log10 CFU/ml of CSF), asmeasured by flow
cytometry. Themedian CrAg LFA titer was 1:8,000 (IQR, 2,000 to
16,000).
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The cryptococcal counts measured by flow cytometry were
strongly correlated with both quantitative culture (Pearson’s r
0.91; P 0.0001) (Fig. 2a) and CrAg titer (Spearman rho 0.75;
P  0.0001). Linear regression showed that the quantitative cul-
ture result could accurately be predicted from flow cytometry
counting (log10 CFU/ml of CSF 1.31 log10 flow count 1.28;
R2  0.82; P  0.0001). The agreement between flow cytometry
counting and quantitative culture was also assessed using a Bland-
Altman plot (Fig. 2b). This showed good agreement between these
two measurements, with a mean difference of0.1 log10 CFU/ml
of CSF and only 6.9% (4/58) of values outside the 95% limits of
agreement. These outlying values were found mainly among
participants with low fungal burdens (500 CFU/ml of CSF),
whereas flow cytometry counting produced values that were
approximately 1- to 2-log10 CFU/ml of CSF higher. Similarly
strong correlation and agreement between the two measure-
ment techniques were also noted when analysis was restricted
to the 36 participants who had not received any antifungal
therapy prior to CSF sampling (Pearson’s r 0.93; P 0.0001
(Fig. 2c); the mean difference was0.30 log10 CFU/ml of CSF,
with 11.1% (4/36) of the values outside the limits of agreement
(Fig. 2d).
These findings suggest that flow cytometry has the ability to
provide a rapid and accurate measurement of fungal burden in
persons with HIV-associated cryptococcal meningitis. If com-
bined with a cryptococcal viability stain (as previously demon-
strated in vitro [4]), flow cytometry could also be used to assess the
response to treatment.
Due to the well-recognized toxicity of amphotericin B (7),
there is considerable interest in short-course regimens, partic-
FIG 1 CSF flow cytometry gating CSF cells (forward scatter [FSC] and side
scatter [SCC]), showing a poor definition of cell subsets due to cryptococci
(a1), CD45 and LIVE/DEAD stain are used to separate cells (a2), FSC-SSC plot
of cryptococci (b), FSC-SSC plot of CSF leukocytes (c), and FSC-SSC plot of
dead CD45 cells.
FIG 2 (a) Scatterplot demonstrating association between flow cytometry counting, and quantitative culture. (b) Bland-Altman plot showing good agreement
between flow counting and quantitative culture (gray area indicates the 95% limits of agreement). (c) Association between flow counting and quantitative culture
among participants who had not received antifungal therapy before CSF sampling. (d) Bland-Altman plot showing agreement between the two techniques,
limited to participants who had not received antifungal therapy before CSF sampling (gray area indicates the 95% limits of agreement).
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ularly in those patients with low fungal burden (8). The results
from quantitative culture are not available in a timely enough
manner to inform clinical decision making, but the rapidity of
the result obtained from flow cytometric cryptococcal count-
ing potentially overcomes this problem. This might allow for a
reduction in drug toxicity, cost, and duration of hospitaliza-
tion. Although this technique does require access to a flow
cytometer, suitable machines are available in many laborato-
ries in sub-Saharan Africa, where they are used to measure CD4
counts. In areas where they are not available, a rapid assess-
ment of fungal burden might be possible using quantitative
microscopy (4).
There were a number of limitations to this study. No cryp-
tococcus-specific stain was used to identify cryptococci; in-
stead, they were assumed to be any CD45 cell found in the
CSF. Given that all participants had laboratory-confirmed
cryptococcal meningitis, a lysis buffer was used to ensure that
no erythrocytes remained in the CSF, and host leukocytes were
excluded using the panleukocyte marker CD45; we feel this is a
reasonable assumption and that our results are valid. However,
to be a fully robust clinical assay, an anticryptococcal stain
would ideally be incorporated into the panel and the assay
validated on CSF samples from patients who do not have CM.
This would have the additional benefit of improving the accu-
racy of flow cytometric counting at low fungal burdens, where
debris or miscellaneous cells may have interfered with the
counting process. In addition, we examined only the use of flow
cytometric counting to assess fungal burden at baseline and did
not assess changes on antifungal therapy. Future work should
aim to incorporate a cryptococcal viability marker to address
this issue, as previously assessed in vitro (4).
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